Phase 3 Study Evaluating Yervoy® (Ipilimumab) for Melanoma in an Adjuvant Setting Meets Primary Endpoint of Recurrence-Free Survival
June 02, 2014 at 07:38 AM EDT
Results demonstrate a significant improvement in recurrence-free survival for an investigational dose of Yervoy vs. placebo for ...
